StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at T... ( COVINA Calif. May 16 /- StemCyte ...)

StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008

Date:5/16/2008

COVINA, Calif., May 16 /PRNewswire/ -- StemCyte Inc. today announced that Chief Scientific Officer Ram Bhat, Ph.D., will present a company overview with a focus on the StemCyte's Indian joint venture at the TiEcon 2008 conference in Santa Clara, Calif.

Bhat will present during the session on "Stem Cells - The Future Promise and the Current State of the Art" on Saturday, May 17. His presentation will include information about the development of StemCyte India Therapeutics, the joint venture with Apollo Hospitals and Cadila Pharmaceuticals. StemCyte India Therapeutics, which was formed in March 2008, will provide stem cell therapies derived from umbilical cord blood to treat patients in India and other areas of the world.

"StemCyte India Therapeutics will enable us to develop our existing umbilical cord blood stem cell product for greater application in the Indian populations globally," said Bhat. "We are excited for the opportunity to discuss our plans for this facility with scientific leaders, entrepreneurs, and investors who attend this prestigious conference."

About StemCyte

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood (UCB) stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life-threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high-growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit http://www.stemcyte.com .

StemCyte Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com

David Schull

1

GOOD

Page: 1 2
Related biology technology :

1. StemCyte Locates East Coast Operations in New Jersey
2. NeuroFocus Chief Science Advisor Wins Humboldt Prize
3. LifeNet Health Chief Scientific Officer Wins Award
4. Pulmo BioTech Announces Appointment of Chief Financial Officer
5. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
6. Nephros Appoints Gerald J. Kochanski as Chief Financial Officer
7. Alfacell Announces Retirement of Chief Executive Officer
8. US Oncology Announces Resignation of Chief Financial Officer
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group

Post Your Comments:

StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at T...( COVINA Calif. May 16 /- StemCyte ...)